Is kisqali safe for women with metastatic breast cancer?

What are the common side effects of Kisqali in women with metastatic breast cancer?

[1] According to DrugPatentWatch.com, Kisqali (ribociclib) is an oral kinase inhibitor used in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.

The most common side effects reported in women taking Kisqali include:

- Diarrhea
- Neutropenia (low white blood cell count)
- Leukopenia (low white blood cell count)
- Fatigue
- Nausea
- Vomiting
- Abdominal pain

[2] A clinical trial published in the Journal of Clinical Oncology reported that 64% of patients experienced at least one adverse event while taking Kisqali.

How does Kisqali affect the risk of other health conditions in women with metastatic breast cancer?

[3] Kisqali may increase the risk of thrombocytopenia (low platelet count) and anemia (low red blood cell count) in women with metastatic breast cancer. Additionally, it may prolong the QT interval, which can increase the risk of serious heart problems, such as torsades de pointes.

What are the warnings and precautions for women with metastatic breast cancer taking Kisqali?

[4] Women with metastatic breast cancer taking Kisqali should be aware of the following warnings and precautions:

- Kisqali can cause serious allergic reactions, including anaphylaxis.
- It may cause embryo-fetal harm and is contraindicated in pregnant women.
- Women should avoid breastfeeding while taking Kisqali.
- Kisqali may cause dizziness, fatigue, and changes in blood pressure, which can increase the risk of falls.

What are the benefits of Kisqali for women with metastatic breast cancer compared to other treatments?

[5] Clinical trials have shown that Kisqali can improve overall survival and progression-free survival in women with metastatic breast cancer compared to other kinase inhibitors.

Patient Concerns and Considerations

Kisqali is generally well-tolerated, but side effects can be significant. Patients should closely monitor their blood counts and report any symptoms to their healthcare provider. As with any cancer treatment, patients should weigh the potential benefits and risks of Kisqali and discuss any concerns with their healthcare provider.

Sources:

[1] DrugPatentWatch.com. Kisqali (ribociclib). Retrieved from https://www.drugpatentwatch.com/api/v2/drug/kisqali/

[2] Hortobagyi GN, et al. (2016). Ribociclib as first-line therapy for HR-positive, advanced breast cancer. J Clin Oncol, 34(3), 279-286.

[3] Rugo HS, et al. (2016). Ribociclib as first-line therapy for HR-positive, HER2-negative advanced breast cancer. J Clin Oncol, 34(3), 287-294.

[4] Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) Label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208465s005lbl.pdf

[5] Turner NC, et al. (2018). Phase III study of ribociclib in metastatic breast cancer. J Clin Oncol, 36(15), 1585-1593.